The 10-second takeaway
For the quarter ended June 30 (Q2), Nxstage Medical beat slightly on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP loss per share shrank.
Margins improved across the board.
Nxstage Medical reported revenue of $59.0 million. The 11 analysts polled by S&P Capital IQ predicted a top line of $58.1 million on the same basis. GAAP reported sales were 9.7% higher than the prior-year quarter's $53.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.07. The 10 earnings estimates compiled by S&P Capital IQ predicted -$0.09 per share. GAAP EPS were -$0.09 for Q2 versus -$0.10 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 37.9%, 280 basis points better than the prior-year quarter. Operating margin was -5.6%, 180 basis points better than the prior-year quarter. Net margin was -8.6%, 170 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $61.9 million. On the bottom line, the average EPS estimate is -$0.05.
Next year's average estimate for revenue is $241.6 million. The average EPS estimate is -$0.28.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 134 members out of 167 rating the stock outperform, and 33 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give Nxstage Medical a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $24.56.
- Add Nxstage Medical to My Watchlist.